Genitourinary Cancer Trial

Prostate, Hormone-Sensitive

Abiraterone Acetate and Antiandrogen Therapy with or without Cabazitaxel and Prednisone in Treating Patients with Metastatic, Castration-Resistant Prostate Cancer Previously Treated with Docetaxel

OR

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for
Extensive Disease following Docetaxel: The CHAARTED2 Trial

 

Physician and Research Staff Educational Material

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

    • Physician Fact Sheet: schema, eligibility criteria, and treatment details
    • Pocket Reference Card: trial schema, study objectives, and eligibility requirements on a pocket-sized card for easy reference when consulting with patients in the office or on rounds

Patient Educational Material

Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. For sites utilizing local IRBs, please submit this in accordance with your local IRB policies prior to use.

    • Study Summary for Patients: study objectives, eligibility criteria, and a simplified schema in lay language to provide a more visual description of the trial to patients.

Information and Assistance from the National Cancer Institute

    • Locations and other information
    • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.

ClinicalTrials.gov ID: NCT03419234

Return to Home Page | Review Other Active Trials